Madrigal Pharmaceuticals Inc annual revenue for fiscal TTM was $1.3 billion, an increase of 33.9% from $958 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Revenue (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1.3B | $958M | $180M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $8M | $15M | $144M | $3M | $1M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Revenue (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $364M | $311M | $321M | $287M | $213M | $137M | $103M | $62M | $15M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More MDGL metrics: Gross Profit · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All MDGL financial statements → Interactive MDGL charts →
About TickerBase · Data methodology & sources · Privacy · Terms